Skip to main content
SpringerLink
Log in

Non-contraceptive Benefits of Hormonal Methods

  • Chapter
  • First Online:
Female and Male Contraception

Part of the book series: Trends in Andrology and Sexual Medicine ((TASM))

  • 1213 Accesses

Abstract

Since their development in the 1960s, hormonal contraceptives (HCs) have been used by hundreds of millions of women to prevent unintended pregnancies. With the spread of their use, a growing number of additional health benefits have emerged, making them not only one of the most reliable methods of contraception, but also an affordable and valuable therapeutic option for various issues. In particular, several studies have confirmed the positive effects of combined oral contraception on menses-related issues, endometriosis, polycystic ovarian syndrome, and bone mineral density. Moreover, the prolonged use of some HCs has been shown to reduce the incidence of different types of cancer, most notably ovarian, endometrial, and colorectal cancer, and their protection seems to last even after their discontinuation.

It is crucial to provide women with correct and updated informations about the risks and benefits of hormonal contraception, so that patients could be actively involved in choosing the most appropriate contraceptive method, based on their needs, health issues, and preferences.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Achievements in Public Health, 1900–1999. Family planning. JAMA. 2000;283:326–31.

    Google Scholar 

  2. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216:580.e1–9.

    Google Scholar 

  3. United Nations, Department of Economic and Social Affairs, Population Division. World contraceptive patterns. 2013.

    Google Scholar 

  4. Dragoman MV. The combined oral contraceptive pill- recent developments, risks and benefits. Best Pract Res Clin Obstet Gynaecol. 2014;28:825–34.

    Google Scholar 

  5. Regidor P-A. Clinical relevance in present day hormonal contraception. Horm Mol Biol Clin Invest. 2019;37:1.

    Google Scholar 

  6. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 2004;190:S5–S22.

    Google Scholar 

  7. Bahamondes L, Valeria Bahamondes M, Shulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. Hum Reprod Update. 2015;21:640–51.

    Google Scholar 

  8. Bitzer J, Amy J-J, Beerthuizen R, Birkhäuser M, Bombas T, Creinin M, Darney PD, Vicente LF, Gemzell-Danielsson K, Imthurn B, Jensen JT, Kaunitz AM, Kubba A, Lech MM, Mansour D, Merki G, Rabe T, Sedlecki K, Serfaty D, Seydoux J, Shulman LP, Sitruk-Ware R, Skouby SO, Szarewski A, Trussell J, Westhoff C. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. J Fam Plann Reprod Health Care. 2013;39:156–9.

    Google Scholar 

  9. Gallo M, Grimes D, Schulz K, Helmerhorst Fm F. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014;1:CD003987.

    Google Scholar 

  10. Girum T, Wasie A. Return of fertility after discontinuation of contraception: a systematic review and meta-analysis. Contracept Reprod Med. 2018;3:9.

    Google Scholar 

  11. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet. 2003;362:185–91.

    Google Scholar 

  12. Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners’ oral contraception study. BMJ. 1999;318:96–100.

    Google Scholar 

  13. Burkman RT, Collins JA, Shulman LP, Williams JK. Current perspectives on oral contraceptive use. Am J Obstet Gynecol. 2001;185:S4–S12.

    Google Scholar 

  14. Huber JC, Bentz E-K, Ott J, Tempfer CB. Non-contraceptive benefits of oral contraceptives. Expert Opin Pharmacother 2008; 10.

    Google Scholar 

  15. The ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update. 2005;11:513–25.

    Google Scholar 

  16. Ju H, Jones M, Mishra G. The Prevalence and Risk Factors of Dysmenorrhea. Epidemiol Rev. 2014;36:104–13.

    Google Scholar 

  17. Rodrigues AC, Gala S, Neves Â, Pinto C, Meirelles C, Frutuoso C, Vítor ME. Dysmenorrhea in adolescents and young adults: prevalence, related factors and limitations in daily living. Acta Medica Port. 2011;24(Suppl 2):383–8; quiz 389–392

    Google Scholar 

  18. Sharma A, Taneja DK, Sharma P, Saha R. Problems related to menstruation and their effect on daily routine of students of a medical college in Delhi, India. Asia Pac J Public Health. 2008;20:234–41.

    Google Scholar 

  19. Thomas SL, Ellertson C. Nuisance or natural and healthy: should monthly menstruation be optional for women? Lancet. 2000;355:922–4.

    Google Scholar 

  20. Lundström V, Gréen K. Endogenous levels of prostaglandin F2alpha and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol. 1978;130:640–6.

    Google Scholar 

  21. Chan WY, Yusoff Dawood M, Fuchs F. Prostaglandins in primary dysmenorrhea: comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives. Am J Med. 1981;70:535–41.

    Google Scholar 

  22. Hauksson A, Ekström P, Juchnicka E, Laudański T, Akerlund M. The influence of a combined oral contraceptive on uterine activity and reactivity to agonists in primary dysmenorrhea. Acta Obstet Gynecol Scand. 1989;68:31–4.

    Google Scholar 

  23. Milsom I, Sundell G, Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception. 1990;42:497–506.

    Google Scholar 

  24. Larsson G, Milsom L, Lindstedt G, Rybo G. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception. 1992;46:327–34.

    Google Scholar 

  25. Hendrix SL, Alexander NJ. Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception. 2002;66:393–9.

    Google Scholar 

  26. Winkler UH, Ferguson H, Mulders JAPA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 μg ethinylestradiol. Contraception. 2004;69:469–76.

    Google Scholar 

  27. Uysal G, Akkaya H, Cagli F, Tutus S, Tayyar AT. A comparison of two different oral contraceptives in patients with severe primary dysmenorrhoea. J Obstet Gynaecol. 2018;38:828–32.

    Google Scholar 

  28. Nilsson L, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol. 1971;110:713–20.

    Google Scholar 

  29. Nilsson L, Sölvell L. Clinical studies on oral contraceptives—a randomized, doubleblind, crossover study of 4 different preparations (Anovlar mite, Lyndiol mite, Ovulen, and Volidan). Acta Obstet Gynecol Scand. 1967;46:3–31.

    Article  CAS  Google Scholar 

  30. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of Menorrhagia. Aust N Z J Obstet Gynaecol. 1991;31:66–70.

    Google Scholar 

  31. Hoaglin DC, Filonenko A, Glickman ME, Wasiak R, Gidwani R. Use of mixed-treatment-comparison methods in estimating efficacy of treatments for heavy menstrual bleeding. Eur J Med Res. 2013;18:17.

    Google Scholar 

  32. Ahrendt H-J, Makalová D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80:436–44.

    Google Scholar 

  33. Fraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2011;16:258–69.

    Google Scholar 

  34. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol. 2011;117:777–87.

    Google Scholar 

  35. Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, DeSanctis Y, Jensen J. Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception. 2012;86:452–7.

    Google Scholar 

  36. Kaunitz AM. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116:1456.

    Google Scholar 

  37. Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2009;113:1104–16.

    Google Scholar 

  38. Hale GE, Fraser IS, Manconi F. Quantitative menstrual blood loss measurement in ovulatory and anovulatory cycles in mid to late reproductive age and the menopause transition. Obstet Gynecol. 2010:249–56.

    Google Scholar 

  39. Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J. Levonorgestrel intrauterine system versus medical therapy for Menorrhagia. N Engl J Med. 2013;368:128–37.

    Google Scholar 

  40. Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol. 2000;96:913–20.

    CAS  PubMed  Google Scholar 

  41. ACOG committee opinion. Premenstrual syndrome. Number 155—April 1995 (replaces no. 66, January 1989). Committee on gynecologic practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1995;50:80–4.

    Article  Google Scholar 

  42. Halbreich U. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder—clinical procedures and research perspectives. Gynecol Endocrinol. 2004;19:320–34.

    Article  CAS  Google Scholar 

  43. Halbreich U. Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectr. 2008;13:566–72.

    Article  Google Scholar 

  44. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338:209–16.

    Google Scholar 

  45. Casson P, Hahn PM, Van Vugt DA, Reid RL. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol. 1990;162:99–105.

    Google Scholar 

  46. Mezrow G, Shoupe D, Spicer D, Lobo R, Leung B, Pike M. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril. 1994;62:932–7.

    Article  CAS  Google Scholar 

  47. Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, Zhang P, Patel H, Foegh M. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Women’s Health Gender-Based Med. 2001;10:561–9.

    Google Scholar 

  48. Freeman EW, Halbreich U, Grubb GS, Rapkin AJ, Skouby SO, Smith L, Mirkin S, Constantine GD. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception. 2012;85:437–45.

    Google Scholar 

  49. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72:414–21.

    Google Scholar 

  50. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol. 2006;195:1311–9.

    Google Scholar 

  51. Eisenlohr-Moul TA, Girdler SS, Johnson JL, Schmidt PJ, Rubinow DR. Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: results of a three-arm randomized controlled trial. Depress Anxiety. 2017;34:908–17.

    Google Scholar 

  52. Mabrouk M, Montanari G, Di Donato N, Del Forno S, Frascà C, Geraci E, Ferrini G, Vicenzi C, Raimondo D, Villa G, Zukerman Z, Alvisi S, Seracchioli R. What is the impact on sexual function of laparoscopic treatment and subsequent combined oral contraceptive therapy in women with deep infiltrating endometriosis? J Sex Med. 2012;9:770–8.

    Google Scholar 

  53. Montanari G, Di Donato N, Benfenati A, Giovanardi G, Zannoni L, Vicenzi C, Solfrini S, Mignemi G, Villa G, Mabrouk M, Schioppa C, Venturoli S, Seracchioli R. Women with deep infiltrating endometriosis: sexual satisfaction, desire, orgasm, and pelvic problem interference with sex. J Sex Med. 2013;10:1559–66.

    Google Scholar 

  54. Grandi G, Xholli A, Ferrari S, Cannoletta M, Volpe A, Cagnacci A. Intermenstrual pelvic pain, quality of life and mood. Gynecol Obstet Investig. 2013;75:97–100.

    Google Scholar 

  55. Fraser I, Weisberg E. Contraception and endometriosis: challenges, efficacy, and therapeutic importance. OAJC. 2015;2015:105.

    Google Scholar 

  56. Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update. 2012;18:682–702.

    Google Scholar 

  57. Tarjanne S, Ng CHM, Manconi F, Arola J, Mentula M, Maneck B, Fraser IS, Heikinheimo O. Use of hormonal therapy is associated with reduced nerve fiber density in deep infiltrating, rectovaginal endometriosis. Acta Obstet Gynecol Scand. 2015;94:693–700.

    Google Scholar 

  58. Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017;107:533–6.

    Google Scholar 

  59. Chapron C, Souza C, Borghese B, Lafay-Pillet M-C, Santulli P, Bijaoui G, Goffinet F, de Ziegler D. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum Reprod. 2011;26:2028–35.

    Google Scholar 

  60. Vercellini P, Somigliana E, Viganò P, De Matteis S, Barbara G, Fedele L. Post-operative endometriosis recurrence: a plea for prevention based on pathogenetic, epidemiological and clinical evidence. Reprod BioMed Online. 2010;21:259–65.

    Google Scholar 

  61. Harada T, Momoeda M, Taketani Y, Hoshiai H, Terakawa N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2008;90:1583–8.

    Google Scholar 

  62. Mabrouk M, Solfrini S, Frascà C, Del Forno S, Montanari G, Ferrini G, Paradisi R, Seracchioli R. A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinilestradiol 3 mg/20 mcg. Gynecol Endocrinol. 2012;28:451–4.

    Google Scholar 

  63. Caruso S, Iraci M, Cianci S, Fava V, Casella E, Cianci A. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 μg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Investig. 2016;39:923–31.

    Google Scholar 

  64. Seracchioli R, Mabrouk M, Frascà C, Manuzzi L, Montanari G, Keramyda A, Venturoli S. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertil Steril. 2010;93:52–6.

    Google Scholar 

  65. Seracchioli R, Mabrouk M, Frascà C, Manuzzi L, Savelli L, Venturoli S. Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertil Steril. 2010;94:464–71.

    Google Scholar 

  66. Vercellini P. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril. 2003;80:560–3.

    Google Scholar 

  67. Zorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet. 2015;292:37–43.

    Google Scholar 

  68. Guzick DS, Huang L-S, Broadman BA, Nealon M, Hornstein MD. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril. 2011;95:1568–73.

    Google Scholar 

  69. Takamura M, Koga K, Osuga Y, Takemura Y, Hamasaki K, Hirota Y, Yoshino O, Taketani Y. Post-operative oral contraceptive use reduces the risk of ovarian endometrioma recurrence after laparoscopic excision. Hum Reprod. 2009;24:3042–8.

    Google Scholar 

  70. Seracchioli R, Mabrouk M, Manuzzi L, Vicenzi C, Frascà C, Elmakky A, Venturoli S. Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis. Hum Reprod. 2009;24:2729–35.

    Google Scholar 

  71. Dunselman GAJ, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400–12.

    Google Scholar 

  72. Grandi G, Barra F, Ferrero S, Sileo FG, Bertucci E, Napolitano A, Facchinetti F. Hormonal contraception in women with endometriosis: a systematic review. Eur J Contracept Reprod Health Care. 2019;24:61–70.

    Google Scholar 

  73. Grandi G, Facchinetti F, Bitzer J. Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle? Eur J Contracept Reprod Health Care. 2017;22:245–6.

    Google Scholar 

  74. Ferrari S, Persico P, Di Puppo F, Vigano P, Tandoi I, Garavaglia E, Giardina P, Mezzi G, Candiani M. Continuous low-dose oral contraceptive in the treatment of colorectal endometriosis evaluated by rectal endoscopic ultrasonography: bowel endometriosis and low-dose pill. Acta Obstet Gynecol Scand. 2012;91:699–703.

    Google Scholar 

  75. Harada T, Kosaka S, Elliesen J, Yasuda M, Ito M, Momoeda M. Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial. Fertil Steril. 2017;108:798–805.

    Google Scholar 

  76. Jensen JT, Schlaff W, Gordon K. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertil Steril. 2018;110:137–152.e1.

    Google Scholar 

  77. Andres M de P, Lopes LA, Baracat EC, Podgaec S. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet. 2015;292:523–9.

    Google Scholar 

  78. Xholli A, Filip G, Previtera F, Cagnacci A. Modification of endometrioma size during hormone therapy containing dienogest. Gynecol Endocrinol. 2020;36:545–9.

    Google Scholar 

  79. Sugimoto K, Nagata C, Hayashi H, Yanagida S, Okamoto A. Use of dienogest over 53 weeks for the treatment of endometriosis. J Obstet Gynaecol Res. 2015;41:1921–6.

    Google Scholar 

  80. Del Forno S, Mabrouk M, Arena A, Mattioli G, Giaquinto I, Paradisi R, Seracchioli R. Dienogest or Norethindrone acetate for the treatment of ovarian endometriomas: can we avoid surgery? Eur J Obstet Gynecol Reprod Biol. 2019;238:120–4.

    Google Scholar 

  81. Caruso S, Cianci A, Iraci M, Fava V, Di Pasqua S, Cianci S. Does nomegestrol acetate plus 17β-estradiol oral contraceptive improve endometriosis-associated chronic pelvic pain in women? J Women’s Health (Larchmt). 2020; .

    Google Scholar 

  82. Ferrero S, Barra F, Leone Roberti Maggiore U. Current and Emerging Therapeutics for the Management of Endometriosis. Drugs. 2018;78:995–1012.

    Google Scholar 

  83. McKinnon B, Mueller M, Montgomery G. Progesterone resistance in endometriosis: an acquired property? Trends Endocrinol Metab. 2018;29:535–48.

    Google Scholar 

  84. Brown J, Crawford TJ, Datta S, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev. 2018; .

    Google Scholar 

  85. Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril. 2003;80:305–9.

    Google Scholar 

  86. Gomes MKO, Ferriani RA, Rosa e Silva JC, Japur de Sá Rosa e Silva AC, Vieira CS, Cândido dos Reis FJ. The levonorgestrel-releasing intrauterine system and endometriosis staging. Fertil Steril. 2007;87:1231–4.

    Google Scholar 

  87. Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, Indhavivadhana S, Leerasiri P. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol. 2012;119:519–26.

    Google Scholar 

  88. de Sá Rosa e Silva ACJ, Rosa e Silva JC, Nogueira AA, Petta CA, Abrão MS, Ferriani RA. The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis. Fertil Steril. 2006;86:742–4.

    Google Scholar 

  89. Johnson NP, Hummelshoj L, World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod. 2013;28:1552–68.

    Google Scholar 

  90. Haberal A, Kayikcioglu F, Gunes M, Kaplan M, Ozdegirmenci O. The effect of the levonorgestrel intrauterine system on uterine artery blood flow 1 year after insertion. Ultrasound Obstet Gynecol. 2006;27:316–9.

    Google Scholar 

  91. Bragheto AM, Caserta N, Bahamondes L, Petta CA. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception. 2007;76:195–9.

    Google Scholar 

  92. Cho S, Nam A, Kim H, Chay D, Park K, Cho DJ, Park Y, Lee B. Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol. 2008;198:373.e1–7.

    Google Scholar 

  93. de Groot PCM, Dekkers OM, Romijn JA, Dieben SWM, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update. 2011;17:495–500.

    Google Scholar 

  94. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7.

    Google Scholar 

  95. Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman J-M, Giagulli VA, Signori C, Zambotti F, Dall’Alda M, Spiazzi G, Zanolin ME, Bonora E. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98:E628–37.

    Google Scholar 

  96. Dumesic DA, Akopians AL, Madrigal VK, Ramirez E, Margolis DJ, Sarma MK, Thomas AM, Grogan TR, Haykal R, Schooler TA, Okeya BL, Abbott DH, Chazenbalk GD. Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight polycystic ovary syndrome women. J Clin Endocrinol Metab. 2016;101:4178–88.

    Google Scholar 

  97. Wu S, Divall S, Nwaopara A, Radovick S, Wondisford F, Ko C, Wolfe A. Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes. 2014;63:1270–82.

    Google Scholar 

  98. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16:347–63.

    Google Scholar 

  99. Palomba S, de Wilde MA, Falbo A, Koster MPH, La Sala GB, Fauser BCJM. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015;21:575–92.

    Google Scholar 

  100. Joham AE, Boyle JA, Zoungas S, Teede HJ. Hypertension in reproductive-aged women with polycystic ovary syndrome and association with obesity. Am J Hypertens. 2015;28:847–51.

    Google Scholar 

  101. Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JSE, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28–38.e25.

    Google Scholar 

  102. Endometrial cancer and oral contraceptives. An individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16:1061–70.

    Google Scholar 

  103. de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014, 2014:CD010813.

    Google Scholar 

  104. Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27:13–24.

    Google Scholar 

  105. van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015;2015:CD010334.

    Google Scholar 

  106. Cosma M, Swiglo BA, Flynn DN, Kurtz DM, Labella ML, Mullan RJ, Elamin MB, Erwin PJ, Montori VM. Clinical review: insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab. 2008;93:1135–42.

    Google Scholar 

  107. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565–92.

    Google Scholar 

  108. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American association of clinical endocrinologists, american college of endocrinology, and androgen excess and pcos society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—part 1. Endocr Pract. 2015;21:1291–300.

    Google Scholar 

  109. Yildiz BO. Approach to the patient: contraception in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100:794–802.

    Google Scholar 

  110. Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril. 2012;98:1053–9.

    Google Scholar 

  111. Coneac A, Muresan A, Orasan MS. Antiandrogenic therapy with ciproterone acetate in female patients who suffer from both androgenetic alopecia and acne vulgaris. Clujul Med. 2014;87:226–34.

    Google Scholar 

  112. Koltun W, Maloney JM, Marr J, Kunz M. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol. 2011;155:171–5.

    Google Scholar 

  113. Palli MBA, Reyes-Habito CM, Lima XT, Kimball AB. A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris. J Drugs Dermatol. 2013;12:633–7.

    CAS  PubMed  Google Scholar 

  114. Joish VN, Boklage S, Lynen R, Schmidt A, Lin J. Use of drospirenone/ethinyl estradiol (DRSP/EE) among women with acne reduces acne treatment-related resources. J Med Econ. 2011;14:681–9.

    Google Scholar 

  115. Borgelt LM, Martell CW. Estradiol valerate/dienogest: a novel combined oral contraceptive. Clin Ther. 2012;34:37–55.

    Google Scholar 

  116. Dokras A. Cardiovascular disease risk in women with PCOS. Steroids. 2013;78:773–6.

    Google Scholar 

  117. Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev. 2013;14:95–109.

    Google Scholar 

  118. Corbould A. Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome? Diab/Metabol Res Rev. 2008;24:520–32.

    Google Scholar 

  119. Dokras A. Noncontraceptive use of oral combined hormonal contraceptives in polycystic ovary syndrome—risks versus benefits. Fertil Steril. 2016;106:1572–9.

    Google Scholar 

  120. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev. 2012;2012:CD006133.

    Google Scholar 

  121. Halperin IJ, Sujana Kumar S, Stroup DF, Laredo SE. The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. Hum Reprod. 2011;26:191–201.

    Google Scholar 

  122. Sitruk-Ware R. Hormonal contraception and thrombosis. Fertil Steril. 2016;106:1289–94.

    Google Scholar 

  123. Okoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003–2008. Am J Obstet Gynecol. 2012;207:377.e1–8.

    Google Scholar 

  124. Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JAC. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2013;185:E115–20.

    Google Scholar 

  125. Merz CNB, Johnson BD, Berga S, Braunstein G, Reis SE, Bittner V, WISE Study Group. Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation. Fertil Steril. 2006;85:1425–31.

    Google Scholar 

  126. Baillargeon J-P, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab. 2005;90:3863–70.

    Google Scholar 

  127. Cottingham J, Hunter D. Chlamydia trachomatis and oral contraceptive use: a quantitative review. Genitourin Med. 1992;68:209–16.

    Google Scholar 

  128. Morrison C, Bright P, Wong E, Kwok C, Yacobson I, Gaydos C, Tucker H, Blumenthal P. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm Dis. 2004;31:561–7.

    Google Scholar 

  129. Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, Sondheimer SJ, Hendrix SL, Amortegui A, Trucco G, Bass DC, Kelsey SF, PID Evaluation and Clinical Health (PEACH) Study Investigators. Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study. Am J Obstet Gynecol. 2001;185:121–7.

    Google Scholar 

  130. Ness RB, Keder LM, Soper DE, Amortegui AJ, Gluck J, Wiesenfeld H, Sweet RL, Rice PA, Peipert JF, Donegan SP, Kanbour-Shakir A. Oral contraception and the recognition of endometritis. Am J Obstet Gynecol. 1997;176:580–5.

    Google Scholar 

  131. Henry-Suchet J. Hormonal contraception and pelvic inflammatory disease. Eur J Contracept Reprod Health Care. 1997;2:263–7.

    Google Scholar 

  132. Burkman R. Oral contraceptives: current status. Clin Obstet Gynecol. 2001;44:62–72.

    Article  CAS  Google Scholar 

  133. Rubin GL, Ory HW, Layde PM. Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol. 1982;144:630–5.

    Google Scholar 

  134. Wølner-Hanssen P, Svensson L, Mårdh PA, Weström L. Laparoscopic findings and contraceptive use in women with signs and symptoms suggestive of acute salpingitis. Obstet Gynecol. 1985;66:233–8.

    PubMed  Google Scholar 

  135. Wølner-Hanssen P, Eschenbach DA, Paavonen J, Kiviat N, Stevens CE, Critchlow C, DeRouen T, Holmes KK. Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA. 1990;263:54–9.

    Google Scholar 

  136. Eschenbach DA, Harnisch JP, Holmes KK. Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors. Am J Obstet Gynecol. 1977;128:838–50.

    Google Scholar 

  137. Wølner-Hanssen P. Oral contraceptive use modifies the manifestations of pelvic inflammatory disease. Br J Obstet Gynaecol. 1986;93:619–24.

    Google Scholar 

  138. Cramer DW, Goldman MB, Schiff I, Belisle S, Albrecht B, Stadel B, Gibson M, Wilson E, Stillman R, Thompson I. The relationship of tubal infertility to barrier method and oral contraceptive use. JAMA. 1987;257:2446–50.

    Article  CAS  Google Scholar 

  139. Farquhar CM. Ectopic pregnancy. Lancet. 2005;366:583–91.

    Google Scholar 

  140. Li C, Zhao W-H, Zhu Q, Cao S-J, Ping H, Xi X, Qin G-J, Yan M-X, Zhang D, Qiu J, Zhang J. Risk factors for ectopic pregnancy: a multi-center case-control study. BMC Pregnancy Childbirth. 2015;15:187.

    Google Scholar 

  141. Peterson HB, Lee NC. The health effects of oral contraceptives: misperceptions, controversies, and continuing good news. Clin Obstet Gynecol. 1989;32:339–55.

    Article  CAS  Google Scholar 

  142. Mol BW, Ankum WM, Bossuyt PM, Van der Veen F. Contraception and the risk of ectopic pregnancy: a meta-analysis. Contraception. 1995;52:337–41.

    Article  CAS  Google Scholar 

  143. Li C, Zhao W-H, Meng C-X, Ping H, Qin G-J, Cao S-J, Xi X, Zhu Q, Li X-C, Zhang J. Contraceptive use and the risk of ectopic pregnancy: a multi-center case-control study. PLoS One. 2014;9:e115031.

    Google Scholar 

  144. Kleerekoper M, Brienza RS, Schultz LR, Johnson CC. Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group. Arch Intern Med. 1991;151:1971–6.

    Article  CAS  Google Scholar 

  145. Williams JK. Noncontraceptive benefits of oral contraceptive use: an evidence-based approach. Int J Fertil Womens Med. 2000;45:241–7.

    CAS  PubMed  Google Scholar 

  146. Michaëlsson K, Baron JA, Farahmand BY, Persson I, Ljunghall S. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet. 1999;353:1481–4.

    Google Scholar 

  147. Pasco JA, Kotowicz MA, Henry MJ, Panahi S, Seeman E, Nicholson GC. Oral contraceptives and bone mineral density: a population-based study. Am J Obstet Gynecol. 2000;182:265–9.

    Google Scholar 

  148. Dayal M, Barnhart KT. Noncontraceptive benefits and therapeutic uses of the oral contraceptive pill. Semin Reprod Med. 2001;19:295–304.

    Google Scholar 

  149. Polatti F, Perotti F, Filippa N, Gallina D, Nappi RE. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception. 1995;51:221–4.

    Article  CAS  Google Scholar 

  150. Lloyd T, Taylor DS, Lin HM, Matthews AE, Eggli DF, Legro RS. Oral contraceptive use by teenage women does not affect peak bone mass: a longitudinal study. Fertil Steril. 2000;74:734–8.

    Google Scholar 

  151. Lloyd T, Petit MA, Lin H-M, Beck TJ. Lifestyle factors and the development of bone mass and bone strength in young women. J Pediatr. 2004;144:776–82.

    Google Scholar 

  152. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs. levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;203:547.e1–547.e10.

    Google Scholar 

  153. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, Gupta JK. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia—a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. 2008;139:169–75.

    Google Scholar 

  154. Gallos ID, Ganesan R, Gupta JK. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Obstet Gynecol. 2013;121:1165–71.

    Google Scholar 

  155. Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M, Dusek L. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16:631–50.

    Google Scholar 

  156. Grimes DA, Economy KE. Primary prevention of gynecologic cancers. Am J Obstet Gynecol. 1995;172:227–35.

    Google Scholar 

  157. Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, Berchuck A, Barrett JC, Rodriguez GC. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol. 2006;103:535–40.

    Google Scholar 

  158. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control. 1999;10:277–84.

    Article  CAS  Google Scholar 

  159. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer. 2006;95:385–9.

    Google Scholar 

  160. Heinemann K, Thiel C, Möhner S, Lewis MA, Raff T, Kühl-Habich D, Heinemann LAJ. Benign gynecological tumors: estimated incidence: results of the German Cohort Study on Women’s Health. Eur J Obstet Gynecol Reprod Biol. 2003;107:78–80.

    Google Scholar 

  161. Tao MH, Xu WH, Zheng W, Zhang Z-F, Gao Y-T, Ruan ZX, Cheng JR, Gao J, Xiang YB, Shu XO. Oral contraceptive and IUD use and endometrial cancer: a population-based case-control study in Shanghai, China. Int J Cancer. 2006;119:2142–7.

    Google Scholar 

  162. Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol. 2014;124:292–9.

    Google Scholar 

  163. Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL, American Society of Clinical Oncology. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol. 2009;27:812–26.

    Google Scholar 

  164. Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol. 1983;117:128–39.

    Google Scholar 

  165. Beral V, Million Women Study Collaborators, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007;369:1703–10.

    Google Scholar 

  166. Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013;122:139–47.

    Google Scholar 

  167. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ. 2007;335:651.

    Google Scholar 

  168. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT. Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology. 2008;19:237–43.

    Google Scholar 

  169. Reade CJ, McVey RM, Tone AA, Finlayson SJ, McAlpine JN, Fung-Kee-Fung M, Ferguson SE. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. J Obstet Gynaecol Can. 2014;36:133–40.

    Google Scholar 

  170. Gadducci A, Sergiampietri C, Tana R. Alternatives to risk-reducing surgery for ovarian cancer. Ann Oncol. 2013;24(Suppl 8):viii47–53.

    Google Scholar 

  171. Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31:4188–98.

    Google Scholar 

  172. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Persson IR. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol. 2001;83:575–85.

    Google Scholar 

  173. Kumle M, Weiderpass E, Braaten T, Adami H-O, Lund E, Norwegian-Swedish Women’s Lifestyle and Health Cohort Study. Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women’s Lifestyle and Health Cohort Study. Br J Cancer. 2004;90:1386–91.

    Google Scholar 

  174. Huusom LD, Frederiksen K, Høgdall EVS, Glud E, Christensen L, Høgdall CK, Blaakaer J, Kjaer SK. Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study. Cancer Causes Control. 2006;17:821–9.

    Google Scholar 

  175. Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer. 2001;84:722–7.

    Google Scholar 

  176. Levi F, Pasche C, Lucchini F, La Vecchia C. Oral contraceptives and colorectal cancer. Dig Liver Dis. 2003;35:85–7.

    Article  CAS  Google Scholar 

  177. Lin J, Zhang SM, Cook NR, Manson JE, Buring JE, Lee I-M. Oral contraceptives, reproductive factors, and risk of colorectal cancer among women in a prospective cohort study. Am J Epidemiol. 2007;165:794–801.

    Google Scholar 

  178. Kabat GC, Miller AB, Rohan TE. Oral contraceptive use, hormone replacement therapy, reproductive history and risk of colorectal cancer in women. Int J Cancer. 2008;122:643–6.

    Google Scholar 

  179. Hannaford P, Elliott A. Use of exogenous hormones by women and colorectal cancer: evidence from the Royal College of General Practitioners’ Oral Contraception Study. Contraception. 2005;71:95–8.

    Google Scholar 

  180. Bosetti C, Bravi F, Negri E, La Vecchia C. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update. 2009;15:489–98.

    Google Scholar 

  181. Newcomb PA, Pocobelli G, Chia V. Why hormones protect against large bowel cancer: old ideas, new evidence. Adv Exp Med Biol. 2008;617:259–69.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gynaecology and Human Reproduction Physiopathology, DIMEC, S. Orsola Hospital, University of Bologna, Bologna, BO, Italy

    Renato Seracchioli, Simona Del Forno & Eugenia Degli Esposti

Authors
  1. Renato Seracchioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simona Del Forno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eugenia Degli Esposti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simona Del Forno .

Editor information

Editors and Affiliations

  1. Department of Medical and Surgical Science, University of Bologna, Clinic of Gynecology and Physiopathology of Reproduction, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

    Maria Cristina Meriggiola

  2. Department of Women’s and Children’s Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

    Kristina Gemzell-Danielsson

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Seracchioli, R., Del Forno, S., Degli Esposti, E. (2021). Non-contraceptive Benefits of Hormonal Methods. In: Meriggiola, M.C., Gemzell-Danielsson, K. (eds) Female and Male Contraception. Trends in Andrology and Sexual Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-70932-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-70932-7_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-70931-0

  • Online ISBN: 978-3-030-70932-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation